Business Wire

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet ...
Nasdaq

Cerus: FDA Approves 12-month Shelf Life For INTERCEPT Platelet Processing Sets

(RTTNews) - Cerus Corporation (CERS) announced the FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. The ...
Business Wire

Cerus Announces Collaboration Agreement With Haemonetics for the Use of Acrodose Platelet Kits With the INTERCEPT Blood System for Platelets

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that it has entered into an agreement with Haemonetics Corporation (NYSE:HAE) for the sale of Haemonetics’ Acrodose ...
Business Wire

Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma

CONCORD, Calif. & AUGUSTA, Ga.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today that Shepeard Community Blood Center (Shepeard) has signed a purchase agreement for the INTERCEPT Blood ...